Document is current
Any future updates will be listed below
-
Authors
Warren, Richard B.
Weiss, Anne https://orcid.org/0000-0002-1738-0519
Felding, Jakob
Sommer, Morten O. A. https://orcid.org/0000-0003-4005-5674
-
Funding
Funding for this research was provided by:
Union Therapeutics
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 20 February 2025
First Online: 5 March 2025
Declarations
:
: Richard B. Warren has received research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, and UCB and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GlaxoSmithKline, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION Therapeutics. Richard B. Warren is Editor-in-Chief of Dermatology and Therapy. Richard B. Warren was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Anne Weiss and Jakob Felding are employees of UNION Therapeutics. Morten O.A. Sommer is an employee and board member of and shareholder in UNION Therapeutics.
: This study was conducted in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and the Declaration of Helsinki and with the approval of national independent ethics committees. All patients provided written informed consent before any study-related activities were carried out, and the study protocol was approved by the relevant local institutional review boards and independent ethics committees. Written patient consent for publication was obtained.
